The main objective of this core Is the enrollment of every patient AML and MDS referred to Washington University into the Tissue Acquisition and Clinical Database protocol ofthe GAML program project. Skin, oral mucosa, bone marrow, peripheral blood leul Specific Aim2 : We will maintain a comprehensive clinical leukemia database that will capture epidemiological data, diseaserelated characteristics, prognostic factors, therapeutic information, and outcomes data from all enrolled AML and MDS patients, with de-identified linkage to corresponding banked tissue specimens.

Public Health Relevance

The specimens collected and the database maintained by Core A are essential to the success of Projects 1- 4 outiined in this proposal. These have served as a unique and invaluable resource both for this Program Project since Its inception, and for extramural projects (TCGA) as well.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA101937-10
Application #
8528766
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Project Start
Project End
Budget Start
2013-04-09
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$266,311
Indirect Cost
$104,397
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Fisher, D A C; Malkova, O; Engle, E K et al. (2017) Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia 31:1962-1974
Uy, G L; Duncavage, E J; Chang, G S et al. (2017) Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia 31:872-881
Cole, Christopher B; Russler-Germain, David A; Ketkar, Shamika et al. (2017) Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest 127:3657-3674
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Duncavage, Eric J; Uy, Geoffrey L; Petti, Allegra A et al. (2017) Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood 129:1397-1401
Shirai, Cara Lunn; White, Brian S; Tripathi, Manorama et al. (2017) Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nat Commun 8:14060
Schroeder, Mark A; Choi, Jaebok; Staser, Karl et al. (2017) The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia. Biol Blood Marrow Transplant :
Zhang, Jin; Griffith, Malachi; Miller, Christopher A et al. (2017) Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes. Exp Hematol 55:19-33
Ali, Alaa M; Weisel, Daniel; Gao, Feng et al. (2017) Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen. Cancer Med 6:2814-2821

Showing the most recent 10 out of 113 publications